Physician profile
Kevin Lu
NPI 1457701831
$10,760.45
in general payments reported to CMS, 2019-2025
33 companies · $2,471 in 2025
The $2,471 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,258 · 2022: $886 · 2023: $2,875 · 2024: $3,270 · 2025: $2,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,129 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Education: $87.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,128.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Education | $87.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,123.70 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,532.23 | 2021-2025 | |
| Paragon 28, INC. | $1,198.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $823.33 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $746.79 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $717.59 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $505.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $492.81 | 2023-2025 | Orencia |
| Lilly USA, LLC | $380.15 | 2023-2025 | Taltz |
| Ucb, INC. | $348.16 | 2022-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $308.94 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $176.19 | 2022-2023 | Lupkynis |
| Genentech USA, INC. | $165.14 | 2022-2024 | Actemra, Rituxan |
| Vektor Medical INC. | $160.25 | 2025 | Vmap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.15 | 2023-2025 | Ofev, Cyltezo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $130.00 | 2022 | |
| Glaxosmithkline, LLC. | $100.02 | 2024-2025 | Benlysta |
| Zimmer Biomet Holdings, INC. | $98.38 | 2025 | Gel-One Cross-Linked Hyaluronate |
| Sandoz INC. | $66.17 | 2023-2024 | Hyrimoz |
| Organon LLC | $60.59 | 2024-2025 | Hadlima |
| Radius Health, INC. | $58.42 | 2024 | Tymlos |
| Kyowa Kirin, INC. | $55.11 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $54.32 | 2022-2024 | Strensiq |
| Scilex Pharmaceuticals INC. | $48.41 | 2024-2025 | |
| Genzyme Corporation | $45.68 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.26 | 2024 | Hyqvia |
| Mallinckrodt Hospital Products INC. | $37.05 | 2025 | Acthar |
| Fresenius Kabi USA, LLC | $33.50 | 2024-2025 | Tyenne |
| Kiniksa Pharmaceuticals International, Plc | $28.09 | 2024 | Arcalyst |
| Tersera Therapeutics LLC | $24.94 | 2025 | Quzyttir |
| Sobi, INC | $18.76 | 2025 | |
| Almatica Pharma LLC | $15.76 | 2024 | Teriparatide |
| Kiniksa Pharmaceuticals, LTD. | $13.85 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.